1-3 of 3
Guozhi Gao, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Catriona HM Jamieson, MD, PhD, Nashat Y Gabrail, MD MRCP, Claudia Lebedinsky, MD, Guozhi Gao, PhD, Moshe Talpaz, MD
Journal: Blood
Blood (2013) 122 (21): 4047.
https://doi.org/10.1182/blood.V122.21.4047.4047
Published: 2013
Journal Articles

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, MBBS, PhD, Claire N Harrison, DM, FRCP, FRCPath, Jorge E. Cortes, MD, Francisco Cervantes, MD, Ruben A. Mesa, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Guozhi Gao, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2013) 122 (21): 393.
https://doi.org/10.1182/blood.V122.21.393.393
Published: 2013
Journal Articles

A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.

Moshe Talpaz, MD, Catriona Jamieson, MD, PhD, Nashat Y Gabrail, MD, Claudia Lebedinsky, MD, Guozhi Gao, PhD, Feng Liu, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD
Journal: Blood
Blood (2012) 120 (21): 2837.
https://doi.org/10.1182/blood.V120.21.2837.2837
Published: 2012